Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medicenna Therapeutics Corp. has unveiled promising preclinical data showcasing the potential of their novel therapies, MDNA11 and Bizaxofusp, in treating aggressive cancers like glioblastoma. These therapies work together to boost immune response and weaken the tumor microenvironment, offering hope for cancers resistant to current treatments. The combination of MDNA11 and Bizaxofusp could revolutionize cancer treatment strategies, particularly for tumors known as ‘cold tumors.’
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.